What question did this study set out to answer?

To address the classification challenges of mixed phenotype acute leukemias and myeloid/lymphoid precursor cell neoplasms.

April 10, 2026

Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024

Key Points

To address the classification challenges of mixed phenotype acute leukemias and myeloid/lymphoid precursor cell neoplasms.
Discussion of the classification issues at the Hematopathology Meeting
Proposal of a genomic classification framework
Analysis of gene mutations including MR and TP53
Identified frequent mixed phenotype in AML-MR cases
Highlighted phenotypic and genetic overlaps in various leukemias
Proposed a new framework to improve diagnostic accuracy for MPAL and related neoplasms

Abstract

Mixed phenotype is frequently identified in AML-MR. Future studies are needed to clarify how cases with MR gene mutations and TP53 mutations should be best classified. Additionally, MPAL, T/myeloid, and ETP-ALL and some genetically defined MPAL, B/myeloid, and B-ALL show phenotypic/genetic overlap and are challenging to diagnose. A genomic classification framework is proposed to separate AML-MR and precursor lymphoid neoplasms from MPAL.

Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024

Key Points

Abstract

Cite This Study